MaaT Pharma (EURONEXT: MAAT ? the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for ...

As part of the regulatory process for the registration of new medicines in Europe, the EMA requires pharmaceutical companies to provide a PIP detailing their strategy for investigation of the new ...

Obtaining the Marketing Authorisation Application (MAA) is a key step in the commercialization of drugs in the EU, and also an important help to promote the global market expansion of pharmaceutical ...

Following a year of strategic expansion, European medicine-related companies are advancing their operations in Vietnam.

SAN FRANCISCO, CA, USA I March 13, 2025 I Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first patient in its Phase 3 ECLIPSE ...

OS Therapies, Inc. , a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that it has been awarded a presentation slot at ...

Anew Health plans a $20M IPO amid slowing revenue growth and market challenges. Discover insights on its expansion plans and ...

Lacutamab is granted European Medicines Agency (EMA) PRIME designation and US Food ... The Sézary syndrome cohort of the study could enable the registration of lacutamab in this indication. • Cohort 2 ...

Jaguar expects first results in Q2 2025 of proof-of-concept investigator-initiated trials of crofelemer for the rare diseases short bowel ...

The Marketing Authorization Application for mavorixafor for the treatment of WHIM syndrome is currently under review by the European Medicines ... be based on X4’s registration dossier submitted ...

OST-HER2 has received Fast Track and Orphan Drug designations from the European Medicines Agency ... Results of Operations” in the Company’s registration statement on Form S-1 filed with ...